WAT Medical introduces ObeEnd, the world’s first weight management wristband, supported by clinical evidence presented at the Canadian Nutrition Society annual conference in May 2024. With obesity rates soaring globally, ObeEnd offers a promising, drug-free solution, utilizing neuromodulation technology to reduce caloric intake and enhance recovery, marking a significant advancement in weight management.
13 May 2024 – WAT Medical, a pioneering force in healthcare solutions, has unveiled ObeEnd, the world’s premier weight management wristband supported by compelling clinical evidence. Groundbreaking research findings were unveiled at the Canadian Nutrition Society annual conference in May 2024.
Obesity, now a global epidemic affecting one in eight individuals worldwide according to the World Health Organization (WHO), has become a pressing concern. With the number of overweight adults skyrocketing to 2.5 billion in 2022, double the figure from 1990, the urgency to combat this health crisis is paramount. The Centers for Disease Control and Prevention (CDC) has recognized obesity as a prevalent and costly disease, contributing to a range of debilitating conditions and premature mortality rates, including heart disease, stroke, diabetes, and cancer.
Existing medical interventions for weight loss, such as surgery or pharmaceuticals like FDA-approved Wegovy (semaglutide injection), often come with drawbacks such as adverse effects, inconsistent outcomes, and challenges in maintaining weight loss post-treatment. Studies indicate rapid weight regain upon discontinuing semaglutide injections, emphasizing the need for alternative solutions.
WAT Medical’s goal is to offer a safe and effective alternative for weight management, with ObeEnd representing a paradigm shift in this endeavor. Utilizing neuromodulation technology, ObeEnd administers targeted electrical impulses via PC6 to reduce gastric secretion and enhance post-exercise recovery. Clinical studies have shown significant reductions in caloric intake and pepsinogen-1 production with ObeEnd use. The mechanism behind its effectiveness is believed to be sympathetic inhibition, which has also proven effective in alleviating symptoms like nausea, vomiting, and reducing blood pressure levels.
The promising clinical outcomes of ObeEnd signify a significant step toward an innovative, drug-free wearable solution for weight management. Ongoing clinical trials, in collaboration with Concordia University, seek to validate these findings further, with additional data expected soon.
